Announcements

Job offersmore »



Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




Oxford University launches MMJ research programme

Oxford University and Kingsley Capital Partners have launched a new research programme to investigate the role of cannabinoids in biology and medicine.

The programme aims to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.

Through an initial investment of up to £10 million provided by Kingsley, funded through its new portfolio company Oxford Cannabinoid Technologies (OCT), and a series of research projects performed by medical research teams, Oxford will seek to identify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.

Ahmed Ahmed, Professor of Gynaecological Oncology at Oxford, said: ‘Cannabinoid research has started to produce exciting biological discoveries and this research programme is a timely opportunity to increase our understanding of role of cannabinoids in health and disease. This field holds great promise for developing novel therapeutic opportunities for cancer patients.’

Associate Professor in Clinical Neurosciences, Zameel Cader said: ‘Endocannabinoid signalling is increasingly recognised as fundamentally important in the development and function of the nervous system. This exciting programme of work has the potential to lead to the development of novel therapies for neurological disorders.’

Oxford and Kingsley will host an International Cannabinoid Biomedicine Conference, designed to increase dialogue in the cannabinoid research space, the first of which will take place in Q4 2017.

Neil Mahapatra, Managing Partner of Kingsley, said: ‘Medical cannabis and cannabinoid medicine is already helping patients with some of the most distressing conditions across the world. However, research into the specific pathways and mechanisms that create this benefit is limited and long overdue. Through OCT, we hope our strategic partnership with Oxford will support the development of innovative new therapies to help millions of people around the world. The partnership gives the UK a global leadership role in this fast-growing field.’

The research programme will develop the results into innovative therapies designed to help improve the quality of life of millions of patients. Over time, OCT will fund additional cannabinoid research programmes with the University across different therapeutic areas. This strategic partnership aims to turn Oxford and OCT into a global centre of excellence in cannabinoid research.

For more information:
www.ox.ac.uk

Publication date: 3/16/2017

 


 

Other news in this sector:

10/17/2017 Will legalized marijuana give a new impulse to Mexico's economy?
10/17/2017 Medicinal marijuana one step away from legalization in Peru
10/17/2017 US (MI): Marijuana degree combines science and business
10/16/2017 Macedonian MMJ grower invests in Heliospectra LEDs
10/16/2017 What is Vapor Pressure Deficit and why does it matter?
10/16/2017 Cronos announces distribution agreement in Germany
10/13/2017 US (NV): Marapharm building third facility in Las Vegas
10/13/2017 Canada: Namaste and Authenticating.com partner in MJ identity verification
10/12/2017 Hydropothecary CEO on competing with the marijuana black market
10/12/2017 Puerto Rico MMJ businesses assess hurricane damage
10/12/2017 CAN (BC): Joint venture converts 1.3 million sq. ft. into MMJ greenhouses
10/11/2017 CAN (ON): Canntrust receives cultivation license for Niagara facility
10/10/2017 US (CA): Bob Echter speaks up for marijuana cultivation
10/10/2017 CAN (ON): Supreme crosses important revenue milestone
10/9/2017 CAN (QC): Hydropothecary wins job creation award
10/9/2017 CAN (ON): Construction in full swing at 7ACRES
10/9/2017 US: FDA hints it may look into marijuana health claims
10/9/2017 CAN (ON): Scientus Pharma gets permission to grow MMJ
10/5/2017 Canada: Trudeau proposes tax on marijuana
10/5/2017 CAN (ON): Supreme to quadruple capacity at 7ACRES hybrid facility